Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 5;27(7):573-578.
doi: 10.1093/oncolo/oyac049.

Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis

Mohamad Bassam Sonbol  1 , Gina L Mazza  2 , Lanyu Mi  2 , Thomas Oliver  1 , Jason Starr  3 , Hallbera Gudmundsdottir  4 , Sean P Cleary  4 , Timothy Hobday  4 , Thorvardur R Halfdanarson  4
Affiliations

Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis

Mohamad Bassam Sonbol et al. Oncologist. .

Abstract

Background: Pancreatic neuroendocrine tumors (pNETs) are rare cancers with outcomes determined by multiple factors including grade, stage, and clinical presentation. In this study, we aimed to determine the prognosis of patients with pNETs using a large population-based database.

Materials and methods: In this population-based study, we identified patients with pNETs from the SEER 18 registry (2000-2016) using a combination of ICD-O-3 and histology codes. We calculated age-adjusted incidence rates using SEER*Stat 8.3.5. In addition, we analyzed overall survival (OS) using the Kaplan-Meier method, and investigated prognostic factors using a multivariable Cox proportional hazards model.

Results: A total of 8944 pNETs patients were identified. Annual incidence rates increased from 0.27 to 1.00 per 100 000. This was largely explained by an increase in number of patients diagnosed with localized disease in more recent years (2012-2016). Median OS was 68 months (95% CI [64, 73]) and 5-year OS rates in localized, regional, and metastatic disease were 83%, 67%, and 28%, respectively. There was a significant improvement in OS for patients diagnosed between 2009 and 2016 (median OS 85 months) compared with those diagnosed between 2000 and 2008 (median OS 46 months) (HR 0.66; 95% CI [0.62, 0.70]). This improvement in OS was consistent across all stages.

Conclusions and relevance: This study shows a steady increase pNETs incidence with notable stage migration to earlier stages in recent years. This increase in incidence is accompanied by a significant improvement in survival across different disease stages.

Keywords: SEER; incidence; neuroendocrine tumors; pancreatic tumors.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Age-adjusted incidence rate by year of diagnosis.
Figure 2.
Figure 2.
Age-adjusted incidence rate by year of diagnosis and stage.
Figure 3.
Figure 3.
(A) Kaplan-Meier curve for overall survival in patients with localized, regional, and distant pNETs. (B) Kaplan-Meier curve for overall survival in patients with grade I, grade II, and grade III pNETs.
Figure 4.
Figure 4.
Kaplan-Meier curve for overall survival by year of diagnosis for: (A) all stages; (B) localized stage; (C) regional stage; (D) metastatic stage.
See this image and copyright information in PMC

References

    1. Halfdanarson TR, Strosberg JR, Tang L, et al. . The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors. Pancreas 2020;49(7):863-881. - PubMed
    1. Di Domenico A, Pipinikas CP, Maire RS, et al. . Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol. 2020;3(1):740. - PMC - PubMed
    1. Chan CS, Laddha SV, Lewis PW, et al. . ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup. Nat Commun. 2018;9(1):4158. - PMC - PubMed
    1. Dasari A, Shen C, Halperin D, et al. . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3(10):1335-1342. - PMC - PubMed
    1. Lepage C, Bouvier AM, Phelip JM, et al. . Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004;53(4):549-553. - PMC - PubMed